Ainos (AIMD) Q2 2024 earnings summary

Executive summary

• Reported a net loss of $3.2M for Q2 2024, a 36% increase year-over-year, driven by higher R&D and SG&A expenses.

• Revenue declined to $0 in Q2 2024 from $28.6K in Q2 2023 due to the cessation of COVID-19 test kit sales; VELDONA Pet supplement sales remain limited.

• Operating loss increased 32% year-over-year to $3.0M in Q2 2024, reflecting continued investment in product development and commercialization.

• Cash and cash equivalents rose to $8.0M as of June 30, 2024, supported by $9M in new convertible note financing.

• Strategic shift from COVID-19 test kits to animal and human drug development, with clinical trials underway for VELDONA and AI-powered POCT devices.

Financial highlights

• Q2 2024 revenue: $0 (down from $28.6K in Q2 2023); H1 2024 revenue: $20.7K (down from $77.7K in H1 2023).

• Q2 2024 net loss: $3.2M (vs. $2.3M in Q2 2023); H1 2024 net loss: $6.5M (vs. $4.9M in H1 2023).

• Operating expenses in Q2 2024 increased 32% year-over-year to $3.0M; R&D up 18% and SG&A up 69%.

• Gross profit was negative $25K in Q2 2024, a slight improvement from negative $27K in Q2 2023.

• Weighted-average shares outstanding for Q2 2024: 6.5M; net loss per share: $(0.49).

Outlook and guidance

• Plans to fund operations over the next 12 months with cash reserves, business revenues, and potential debt financing.

• Expects continued growth in R&D expenses as clinical trials for VOC POCT and VELDONA drug candidates accelerate.

• Next-Gen Ainos Flora VOC POCT device targets Q3 2024 for design completion and Q4 for clinical trial kickoff.

• VELDONA FCGS clinical trial in Taiwan aims to enroll 30 subjects by end-2024, with report expected in Q1 2025.

• May seek additional capital through equity or debt if current resources prove insufficient.